Targeting cellular entry, cell survival, and pathogenicity by dynein light chain 1/PIN in human cells
View Patent ↗Methods of modulating macropinocytosis in cells of a target cell population by modulating the binding of Pak1 to DLC1/PIN are disclosed. In addition, the invention provides for methods of screening for modulators of macropinocytosis that involve determining whether a candidate substance inhibits or promotes the binding of Pak1 to DLC1/PIN. Also disclosed are methods of reducing cell proliferation in a target cell population, methods of inhibiting growth and survival of a cancer cell, methods of inhibiting the invasiveness of a cancer cell, and methods of treating viral infection using an agent that modifies the binding of Pak1 to DLC1/PIN.
1. A purified composition comprising a dynein light chain-1/protein inhibitor of nitric oxide synthase (DLC1/PIN) polypeptide having a mutation in SEQ ID NO:2, wherein said polypeptide comprises activity that inhibits binding of DLC1/PIN to p21-activated protein kinase 1 (Pak1) and wherein said polypeptide comprises a DLC1/PIN polypeptide lacking serine 88 of DLC1/PIN, a DLC1/PIN polypeptide lacking the C-terminal 19 amino acids of DLC1/PIN, a DLC1/PIN polypeptide lacking the C-terminal 23 amino acids of DLC1/PIN, or a mixture thereof.
2. The composition of claim 1 , further defined as a pharmaceutical composition.
3. The composition of claim 2 , wherein said composition is dispersed in a pharmaceutically acceptable excipient.
4. A purified composition comprising a mutant dynein light chain-1/protein inhibitor of nitric oxide synthase (DLC1/PIN) polypeptide, wherein said mutant polypeptide comprises activity that inhibits binding of DLC1/PIN to p21-activated protein kinase 1 (Pak1) and wherein said mutant polypeptide comprises a DLC1/PIN polypeptide lacking seine 88 of DLC1/PIN, a DLC1/PIN polypeptide lacking the C-terminal 19 amino acids of DLC1/PIN, a DLC1/PIN polypeptide lacking the C-terminal 23 amino acids of DLC1/PIN, or a mixture thereof, wherein the DLC1/PIN polypeptide lacking seine 88 of DLC1/PIN comprises SEQ ID NO:4.
5. A purified composition comprising a mutant dynein light chain-1/protein inhibitor of nitric oxide synthase (DLC1/PIN) polypeptide, wherein said mutant polypeptide comprises activity that inhibits binding of DLC1/PIN to p21-activated protein kinase 1 (Pak1) and wherein said mutant polypeptide comprises a DLC1/PIN polypeptide lacking serine 88 of DLC1/PIN, a DLC1/PIN polypeptide lacking the C-terminal 19 amino acids of DLC1/PIN, a DLC1/PIN polypeptide lacking the C-terminal 23 amino acids of DLC1/PIN, or a mixture thereof, wherein the DLC1/PIN polypeptide lacking the C-terminal 19 amino acids of DLC1/PIN comprises SEQ ID NO:3.
6. A purified composition comprising a mutant dynein light chain-1/protein inhibitor of nitric oxide synthase (DLC1/PIN) polypeptide, wherein said mutant polypeptide comprises activity that inhibits binding of DLC1/PIN to p21-activated protein kinase 1 (Pak1) and wherein said mutant polypeptide comprises a DLC1/PIN polypeptide lacking seine 88 of DLC1/PIN, a DLC1/PIN polypeptide lacking the C-terminal 19 amino acids of DLC1/PIN, a DLC1/PIN polypeptide lacking the C-terminal 23 amino acids of DLC1/PIN, or a mixture thereof, wherein the DLC1/PIN polypeptide lacking the C-terminal 23 amino acids of DLC1/PIN comprises SEQ ID NO:11.